MTOR and diabetes mellitus: Mistreatment of tuberculosis (TB) vaccination (Al-Attiyah et al., 2009), alteration of gut microbiota (Caricilli et al., 2013), intervention effects through phosphatidylinositol 3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway (Blagosklonny, 2013) and the inhibition of delta-6-desaturase (D6D) enzyme activity by 2,2-diphenyl-5-(4-[[(1 E)-pyridin-3-yl-methylidene]amino]piperazin-1-yl) pentanenitrile (SC-26196), an inhibitor of D6D, are used to treat DM (Obukowicz et al., 1998).